CannAssure Therapeutics

Medical Cannabis Products

Health Tech & Life Sciences
Public on TASE on Dec, 2018

Company Overview

Snapshot

Founded in January 2016 by Nir Peles, CannAssure Therapeutics operates with 1–10 employees. The company has raised $3.44M across two funding rounds and went public on the TASE in December 2018.

Business overview

CannAssure Therapeutics develops and commercializes a range of medical cannabis products and pharmaceutical cannabinoid medicines. The company focuses on enhancing treatment and improving quality of life through a holistic integrated production system, including advanced indoor aeroponic grow facilities and extraction processes, supported by scientific research and development. Operating in accordance with IMC-GAP standards, CannAssure tests its cultivated cannabis and manufactured products at various stages to ensure purity, effectiveness, stability, and consistency. The company serves the medical cannabis market, leveraging expertise from its spin-off origins from food manufacturer Solbar Food Technologies.

Strategic signal

In February 2022, CannAssure secured exclusivity for the Freud cannabis strain, indicating a strategic move to differentiate its product offerings and potentially capture a larger share of the medical cannabis market through proprietary genetics. This development signals the company's focus on product innovation and market positioning within the competitive health tech and life sciences sector.

Company Intelligence Q&A

When did CannAssure Therapeutics go public?
CannAssure Therapeutics went public on the TASE in December 2018.
What was a key product development for CannAssure Therapeutics in early 2022?
In February 2022, CannAssure Therapeutics secured exclusivity for the Freud cannabis strain, enhancing its product portfolio.
What strategic partnership did CannAssure Therapeutics announce in January 2019?
In January 2019, CannAssure Therapeutics announced a strategic partnership with Cannika Holdings.
What distribution agreement did CannAssure Therapeutics sign in December 2020?
In December 2020, CannAssure Therapeutics and DanCann Pharma signed an exclusive distribution agreement for Denmark, Norway, Sweden, and Finland.
What patent was granted to CannAssure Therapeutics in August 2021?
In August 2021, CannAssure Therapeutics was granted a patent by the Israel Patents Authority for an oral delivery method of cannabis and cannabinoid compositions.

External links